MA43283A - Procédés et compositions pour le traitement du cancer - Google Patents

Procédés et compositions pour le traitement du cancer

Info

Publication number
MA43283A
MA43283A MA043283A MA43283A MA43283A MA 43283 A MA43283 A MA 43283A MA 043283 A MA043283 A MA 043283A MA 43283 A MA43283 A MA 43283A MA 43283 A MA43283 A MA 43283A
Authority
MA
Morocco
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
MA043283A
Other languages
English (en)
Other versions
MA43283B1 (fr
Inventor
David Scheinberg
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA43283A publication Critical patent/MA43283A/fr
Publication of MA43283B1 publication Critical patent/MA43283B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001141—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA43283A 2015-11-20 2016-11-18 Composition pour le traitement du cancer MA43283B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562258134P 2015-11-20 2015-11-20
PCT/US2016/062865 WO2017087857A1 (fr) 2015-11-20 2016-11-18 Procédés et compositions pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA43283A true MA43283A (fr) 2018-09-26
MA43283B1 MA43283B1 (fr) 2022-08-31

Family

ID=58717878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43283A MA43283B1 (fr) 2015-11-20 2016-11-18 Composition pour le traitement du cancer

Country Status (21)

Country Link
US (1) US11033613B2 (fr)
EP (2) EP4130026A1 (fr)
JP (4) JP6991969B2 (fr)
KR (2) KR20250099263A (fr)
CN (4) CN116327902A (fr)
AU (2) AU2016356708B2 (fr)
CA (2) CA3255544A1 (fr)
CY (1) CY1125628T1 (fr)
DK (1) DK3377516T3 (fr)
ES (1) ES2926386T3 (fr)
HR (1) HRP20220994T1 (fr)
HU (1) HUE059694T2 (fr)
LT (1) LT3377516T (fr)
MA (1) MA43283B1 (fr)
MD (1) MD3377516T2 (fr)
PL (1) PL3377516T3 (fr)
PT (1) PT3377516T (fr)
RS (1) RS63561B1 (fr)
SI (1) SI3377516T1 (fr)
SM (1) SMT202200370T1 (fr)
WO (1) WO2017087857A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9265816B2 (en) * 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CA3035591A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
WO2019006401A2 (fr) * 2017-06-30 2019-01-03 Advaxis, Inc. Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms hétéroclitique et procédés d'utilisation correspondants
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CN111655714A (zh) * 2017-11-08 2020-09-11 阿德瓦希斯公司 来自癌症相关蛋白的免疫原性异变肽及其使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
WO2020071551A1 (fr) * 2018-10-05 2020-04-09 株式会社癌免疫研究所 Médicament prophylactique ou thérapeutique contre une tumeur maligne
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
KR20220010712A (ko) * 2019-04-10 2022-01-26 에스엘에스지 리미티드 엘엘씨 Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법
US20220396839A1 (en) 2019-11-12 2022-12-15 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
BR112022020285A2 (pt) * 2020-04-07 2022-12-06 Metanoi Therapeutics Inc Formulação de etanolamina para tratar carcinoma epitelial de ovário
WO2021231376A2 (fr) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs méthodes d'utilisation
EP4211149A4 (fr) 2020-09-09 2024-10-09 Cue Biopharma, Inc. Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
CA2103577A1 (fr) 1991-02-07 1992-08-08 Michael Kahn Structures a conformation restreinte mimetiques de tours beta et de saillies beta et peptides en contenant
WO1995004064A1 (fr) 1993-07-29 1995-02-09 The Regents Of The University Of California Leurres polynucleotidiques inhibant l'expression du complexe d'histocompatibilite majeure ii, et applications
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
WO2001025273A2 (fr) 1999-10-04 2001-04-12 Corixa Corporation Compositions et methodes se rapportant a une immunotherapie specifique a wt1
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003106682A1 (fr) 2002-06-12 2003-12-24 中外製薬株式会社 Peptide antigene du cancer a restriction hla-a24
CA2530184C (fr) 2003-06-27 2015-10-06 Haruo Sugiyama Methode de selection des patients candidats au vaccin wt1
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
EP2478913A1 (fr) 2003-12-01 2012-07-25 Sloan-Kettering Institute For Cancer Research Analogues peptidiques synthétiques de liaison à l'antigène histocompatibilité et leurs utilisations
US20060127409A1 (en) 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
CA2626238C (fr) 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
DE102006014261A1 (de) 2006-03-28 2007-10-04 Dr.Ing.H.C. F. Porsche Ag Luftleitvorrichtung für ein Fahrzeug
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
JP5478260B2 (ja) 2007-12-05 2014-04-23 株式会社癌免疫研究所 癌ワクチン組成物
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
CA2861206C (fr) * 2012-01-13 2021-07-06 Richard J. O'reilly Peptides wt-1 immunogenes et leurs procedes d'utilisation
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
WO2014144885A2 (fr) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccins anticancéreux et méthodes de traitement les utilisant
TWI617309B (zh) * 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
CA3156357A1 (fr) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunotherapie
CN106459992A (zh) * 2014-03-17 2017-02-22 塔皮穆内公司 核酸分子疫苗组合物及其用途
US20180140691A1 (en) * 2015-05-20 2018-05-24 Sumitomo Dainippon Pharma Co., Ltd. Combination use of wt1 antigen peptide and immunomodulator
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro

Also Published As

Publication number Publication date
ES2926386T3 (es) 2022-10-25
AU2022202973B2 (en) 2025-07-24
SMT202200370T1 (it) 2022-11-18
KR20180094922A (ko) 2018-08-24
CN108431022A (zh) 2018-08-21
KR20250099263A (ko) 2025-07-01
CN108431022B (zh) 2022-08-09
CA3005896A1 (fr) 2017-05-26
AU2016356708B2 (en) 2022-02-03
PL3377516T3 (pl) 2022-10-10
PT3377516T (pt) 2022-09-23
JP2018538265A (ja) 2018-12-27
CA3255544A1 (en) 2026-03-02
MD3377516T2 (ro) 2022-10-31
AU2016356708A1 (en) 2018-07-05
AU2022202973A1 (en) 2022-05-26
RS63561B1 (sr) 2022-10-31
CN116327903A (zh) 2023-06-27
EP4130026A1 (fr) 2023-02-08
LT3377516T (lt) 2022-09-26
CN116327902A (zh) 2023-06-27
JP6991969B2 (ja) 2022-03-03
US11033613B2 (en) 2021-06-15
EP3377516B1 (fr) 2022-06-15
US20180339030A1 (en) 2018-11-29
CN115920017A (zh) 2023-04-07
JP2026053495A (ja) 2026-03-25
WO2017087857A1 (fr) 2017-05-26
KR102823333B1 (ko) 2025-06-23
SI3377516T1 (sl) 2023-01-31
HRP20220994T1 (hr) 2022-11-11
CA3005896C (fr) 2025-09-23
HUE059694T2 (hu) 2022-12-28
EP3377516A1 (fr) 2018-09-26
DK3377516T3 (da) 2022-09-19
JP2024041809A (ja) 2024-03-27
JP2022033926A (ja) 2022-03-02
MA43283B1 (fr) 2022-08-31
EP3377516A4 (fr) 2019-06-26
CY1125628T1 (el) 2026-02-25

Similar Documents

Publication Publication Date Title
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3645739A4 (fr) Procédés et compositions pour le traitement du mélanome
MA47613A (fr) Compositions et procédés de traitement du cancer
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3288382A4 (fr) Procédés de traitement du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3359157A4 (fr) Procédés et compositions pour le traitement de tumeurs et de cancers métastasés et résistants
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer
EP3386522A4 (fr) Compositions et méthodes pour le traitement du cancer du sein métastatique her2-positif